Dimitris Korovesis is an Assistant Professor of Biochemistry at Aristotle University of Thessaloniki and an interdisciplinary chemical biologist whose research integrates organic synthesis, advanced imaging, chemical proteomics and disease-model biology. He will supervise DC1 (TR-FRET dimerization reporters for EGFR, BRAF and LTK under ATP-locked conditions).
His work spans kinase drug discovery beyond conventional active-site inhibition, photoaffinity and activity-based probe development, proteome-wide target/selectivity profiling and targeted protein degradation.
His laboratory applies these approaches to cancer and neurodegeneration, with particular interests in ALS, oxidative proteotoxic stress, mitochondrial quality control and OxiPTACs, using mammalian systems and complementary models such as C. elegans. His independent research programme is supported by competitive European and US funding, including an NIH/NCI IMAT R61 award, a U.S. Department of Defense ALS Research Program Therapeutic Idea Award, and MSCA/ERA funding
